2025-20

RESOLUTION

Subject: Ivermectin Being Sold Over the Counter

Submitted by: Monalisa Tailor, MD

Referred to: Reference Committee

WHEREAS, the U.S. Food and Drug Administration (FDA) has the critical responsibility of ensuring the safety and effectiveness of drugs available to the public; and

WHEREAS, the FDA has not authorized or approved ivermectin for use in preventing or treating COVID-19 in humans or animals; and

WHEREAS, ivermectin is used off-label for parasitic infections and dosed based on weight; and

WHEREAS, large doses of ivermectin can be dangerous and potentially lead to serious side effects including nausea, vomiting, diarrhea, hypotension, allergic reactions, dizziness, ataxia, seizures, coma, and Steven Johnson syndrome; and

WHEREAS, some ivermectin products are specifically formulated for animal use and can contain concentrations and inactive ingredients that are unsafe for human consumption; and

WHEREAS, off-label use of drugs carries inherent risks, and the unregulated sale of ivermectin over the counter could exacerbate these risks and potentially lead to misuse; and

WHEREAS, the state of Tennessee, Arkansas, Louisiana, and Idaho have passed legislation to allow ivermectin to be sold over the counter to patients; now, therefore, be it

RESOLVED, that KMA oppose legislation approving the over-the-counter sale of ivermectin for human use, especially for conditions not approved by the U.S. Food and Drug Administration (FDA); and be it further

RESOLVED, that KMA urge individuals to consult with their healthcare providers before taking any medication, including ivermectin, to ensure its appropriate use and minimize potential risks.

DRAFT